GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models

10-Apr-2006

Ganymed Pharmaceuticals AG announced that several monoclonal lead antibodies directed against the company's GC182 cancer target have shown excellent efficacy against solid human tumors in mouse xenograft models. No toxicity was observed. The results fully confirm earlier experiments, where antibodies directed against GC182 proved to be very effective against cancer cells that expressed the target.

The GC182 target is a cell surface protein that is involved in cell-cell interactions. It was shown to be expressed with high prevalence and unique specificity in several solid cancers with high medical need (approx. 80% stomach cancers, 30% esophagus cancers, 25% lung and pancreatic cancers). The GC182 cell surface epitope that is targeted by GANYMED's antibodies is identical in mouse and man, and highly similar in other mammalian species. Thus, mouse xenograft models with GANYMED's GC182 antibodies can be considered as highly predictive pre-clinical models.

"This excellent animal data fully confirms our earlier analysis based on human immunohistochemistry and cell culture data." said Dr. Özlem Türeci, CSO and co-founder of GANYMED. "The experiments clearly demonstrate that our antibodies are highly effective against tumors that express GC182, without any apparent toxicity."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous